United Kingdom· GB-APID-35813711000001108
Brineura 150mg/5ml solution for infusion vials
A cerliponase alfa product containing cerliponase alfa, registered in United Kingdom by BioMarin (U.K.) Ltd. The same ATC class is registered in 10 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Cerliponase alfa is registered in 10 of 19 countries.
Countries holding a registration under ATC A16AB17 (cerliponase alfa), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 6 of them publish a price we can compare per daily dose
Cerliponase alfa · ATC A16AB17
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Cerliponase alfa
- Manufacturer
- BioMarin (U.K.) Ltd
- Country
- United Kingdom (GB)
- ATC code
- A16AB17
- ATC class
- Cerliponase alfa
- Defined daily dose
- 21 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin05391524461060
- gtin05391524461985
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Cerliponase alfa in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumBrineura 150 mgBioMarin International
- CanadaBRINEURABIOMARIN INTERNATIONAL LIMITED
- CzechiaBRINEURABioMarin International Limited, Dublin
- SpainBRINEURA 150 MG SOLUCION PARA PERFUSIONBiomarin International Limited
- FinlandBrineuraBiomarin International Limited
- FranceBRINEURA 150 mg, solution pour perfusionBIOMARIN INTERNATIONAL LIMITED (IRLANDE)
- IrelandBrineura 150 mg solution for infusionBioMarin International Limited
- IcelandBrineuraBioMarin International Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Brineura
- Liechtenstein · Brineura
- Norway · Brineura
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/46015a3a-97e6-4b79-be3c-52a2238aad19 GET /v1/drugs/46015a3a-97e6-4b79-be3c-52a2238aad19?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "35813711000001108",
"desc": "Brineura 150mg/5ml solution for infusion vials (BioMarin (U.K.) Ltd)",
"form": "Solution for infusion",
"vpid": "35813511000001103",
"source": "dmd",
"vtm_id": "775134003",
"strength": "30 mg",
"substance": "Cerliponase alfa",
"ingredient": "Cerliponase alfa",
"supplier_code": "10075811000001102"
}See everything about cerliponase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.